Rituximab (166 patients with Refractory/ relapsed FL, ORR 48%)[8,77,78]R-GMCSF (49 Patients with relapsed FL, ORR 74% [79]R-bendamustine (33 patients with Relapsed FL or MCL, ORR 70%)[80,81]R-CHOP (63 Untreated patients of DLBCL, ORR 90%) [82]